Who are bupropion & Citalopram's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nefopam administration and prelevment, Nefopam ampule.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bupropion-citalopram.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

bupropion & Citalopram — Competitive Intelligence Brief

bupropion & Citalopram (bupropion & Citalopram) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidepressant combination (NDRI + SSRI). Area: Psychiatry / Mental Health.

marketed Antidepressant combination (NDRI + SSRI) Norepinephrine transporter, dopamine transporter, serotonin transporter Psychiatry / Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

bupropion & Citalopram (bupropion & Citalopram) — University of Colorado, Denver. This combination blocks the reuptake of norepinephrine and dopamine (bupropion) and serotonin (citalopram) to increase their availability in the brain.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
bupropion & Citalopram TARGET	bupropion & Citalopram	University of Colorado, Denver	marketed	Antidepressant combination (NDRI + SSRI)	Norepinephrine transporter, dopamine transporter, serotonin transporter
Nefopam administration and prelevment	Nefopam administration and prelevment	University Hospital, Rouen	marketed	Non-opioid analgesic; monoamine reuptake inhibitor	Norepinephrine transporter, dopamine transporter, serotonin transporter
Nefopam ampule	Nefopam ampule	Ministry Of Health / Nineveh Health Directorate	phase 3	Non-opioid analgesic; monoamine reuptake inhibitor	Norepinephrine transporter, dopamine transporter, serotonin transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antidepressant combination (NDRI + SSRI) class)

University of Colorado, Denver · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). bupropion & Citalopram — Competitive Intelligence Brief. https://druglandscape.com/ci/bupropion-citalopram. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab